Pfizer Geodon Label Adds Bipolar Claim, Modified Class Diabetes Warning
Executive Summary
Pfizer plans to highlight additional data on weight gain among patients treated with other antipsychotics in promoting a new Geodon indication for acute bipolar mania
You may also be interested in...
CATIE Suggests Zyprexa Useful As Initial Schizophrenia Treatment – NEJM
Results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study suggest Lilly's Zyprexa may be well suited as initial therapy in the treatment of schizophrenia, according to an editorial accompanying the study
CATIE Suggests Zyprexa Useful As Initial Schizophrenia Treatment – NEJM
Results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study suggest Lilly's Zyprexa may be well suited as initial therapy in the treatment of schizophrenia, according to an editorial accompanying the study
Geodon, Abilify Have Low Diabetes Risk, ADA Says; Lilly Disagrees
An American Diabetes Association "consensus" statement on antipsychotics and the risk of diabetes may help Pfizer and Bristol-Myers Squibb make the case to FDA to exempt Geodon and Abilify from class labeling